NVS

Novartis
D

NVS

Arincen80/100B

Novartis income statement 1998–2026

56.31B USD over the last twelve months, and 54.81B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
56.31B54.81B51.72B46.66B43.46B43.97B49.90B48.68B46.10B43.40B49.44B
Revenue growth
-0.12%+5.97%+10.85%+7.36%-1.17%-11.87%+2.51%+5.59%+6.21%-12.20%-1.89%
Cost of revenue
14.29B13.69B12.83B12.47B11.58B11.74B15.12B14.43B14.51B13.63B17.52B
Gross profit
42.02B41.12B38.90B34.19B31.88B32.24B34.78B34.25B31.59B29.77B31.92B
Gross margin
74.62%75.02%75.20%73.27%73.35%73.31%69.70%70.37%68.52%68.59%64.56%
Research and development
13.49B10.74B10.02B11.37B9.17B8.64B8.98B9.40B8.49B8.39B9.04B
Selling, general and administrative
12.90B13.31B12.57B12.52B12.19B12.83B14.20B14.37B13.72B12.47B14.19B
Operating expenses
27.68B23.48B24.35B24.42B23.93B22.18B24.63B25.17B23.19B21.07B23.65B
14.33B17.64B14.54B9.77B7.95B10.06B10.15B9.09B8.40B8.70B8.27B
Operating income growth
-18.36%+21.31%+48.88%+22.94%-20.98%-0.95%+11.73%+8.13%-3.44%+5.25%-7.90%
Operating margin
25.46%32.19%28.12%20.94%18.28%22.87%20.35%18.67%18.23%20.05%16.72%
Interest income
—374.91M567.68M629.24M377.74M71.00M91.00M245.25M292.67M110.00M43.00M
Interest expense
1.58B1.19B1.04B876.12M834.62M905.00M921.00M902.93M973.22M802.00M729.00M
Other non-operating income
-1.69B-638.25M-904.00M-646.00M-769.00M14.47B-274.00M-146.00M5.69B400.00M-451.00M
Pretax income
12.65B16.44B13.64B9.12B7.18B24.53B9.88B8.94B14.10B9.10B7.82B
Income tax
2.63B2.40B1.70B551.00M1.13B1.63B1.81B1.79B1.30B1.60B1.12B
Effective tax rate
20.80%14.59%12.47%6.04%15.72%6.62%18.29%20.06%9.19%17.61%14.32%
10.03B13.98B11.94B14.85B6.96B24.02B8.07B11.73B12.61B7.70B6.71B
Net income growth
-30.29%+17.11%-19.59%+113.52%-71.05%+197.58%-31.20%-6.97%+63.72%+14.76%-62.26%
Net margin
17.82%25.51%23.09%31.83%16.00%54.63%16.18%24.10%27.36%17.75%13.58%
Basic shares
1.91B1.94B2.02B2.08B2.18B2.24B2.28B2.29B2.32B2.35B2.38B
Diluted shares
1.92B1.96B2.04B2.09B2.20B2.26B2.30B2.32B2.34B2.37B2.40B
Change in diluted shares
-2.78%-3.93%-2.72%-4.78%-2.79%-1.57%-0.99%-1.07%-1.14%-1.21%-1.56%
EPS (basic)
5.257.255.927.153.1910.713.543.125.443.282.82
EPS (diluted)
5.247.195.877.103.1710.633.523.085.383.252.80
EPS growth
-28.32%+22.49%-17.32%+123.97%-70.18%+201.99%+14.29%-42.75%+65.54%+16.07%-61.59%
Dividends per share
4.743.993.203.503.333.203.092.572.672.462.47
Dividend growth
+18.68%+24.87%-8.58%+5.22%+3.94%+3.62%+20.26%-3.76%+8.41%-0.58%-1.95%
EBITDA
21.78B22.99B20.72B18.26B14.68B30.91B17.21B15.62B20.24B14.59B14.57B
EBITDA margin
38.69%41.94%40.05%39.12%33.78%70.30%34.49%32.08%43.90%33.61%29.47%
EBIT
14.22B17.63B14.65B9.98B7.98B25.32B10.75B9.79B15.03B9.85B8.52B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Novartis's income statement

Source: Financial Modeling Prep